Fibroblast growth factor signaling in nonsmall-cell lung cancer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Despite recent progress in the treatment on nonsmall cell lung cancer (NSCLC), outcomes remain suboptimal. Treatment advances that target the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways highlight the need to understand the multiple convergent growth factor signaling pathways involved in the pathogenesis of NSCLC. Signaling through fibroblast growth factors (FGF), long recognized for its pro-angiogenic activity, has recently emerged as a contributing factor in the pathogenesis and progression of NSCLC through an autocrine signaling loop. In addition, this pathway may function as a mechanism of resistance to anti-EGFR and anti-VEGF treatment. Clinical experience with FGF receptor (FGFR) inhibitors is mounting, and more specific inhibitors of this signaling pathway are in development. This review describes the structure of the FGF signaling pathway, delineates its dual roles in angiogenesis and proliferation in NSCLC, evaluates FGF ligand and receptor expression as prognostic biomarkers in NSCLC, and discusses the development of FGF pathway inhibitors for the treatment of lung malignancies.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalClinical Lung Cancer
Volume13
Issue number2
DOIs
StatePublished - Mar 2012

Fingerprint

Fibroblast Growth Factors
Non-Small Cell Lung Carcinoma
Fibroblast Growth Factor Receptors
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Autocrine Communication
Intercellular Signaling Peptides and Proteins
Biomarkers
Ligands
Lung
Neoplasms

Keywords

  • Angiogenesis
  • Cellular proliferation
  • Fibroblast growth factor receptor
  • Fibroblast growth factors
  • Nonsmall-cell lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Fibroblast growth factor signaling in nonsmall-cell lung cancer. / Semrad, Thomas; Mack, Philip.

In: Clinical Lung Cancer, Vol. 13, No. 2, 03.2012, p. 90-95.

Research output: Contribution to journalArticle

@article{ef7363d826024c86b76252da7a294bd2,
title = "Fibroblast growth factor signaling in nonsmall-cell lung cancer",
abstract = "Despite recent progress in the treatment on nonsmall cell lung cancer (NSCLC), outcomes remain suboptimal. Treatment advances that target the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways highlight the need to understand the multiple convergent growth factor signaling pathways involved in the pathogenesis of NSCLC. Signaling through fibroblast growth factors (FGF), long recognized for its pro-angiogenic activity, has recently emerged as a contributing factor in the pathogenesis and progression of NSCLC through an autocrine signaling loop. In addition, this pathway may function as a mechanism of resistance to anti-EGFR and anti-VEGF treatment. Clinical experience with FGF receptor (FGFR) inhibitors is mounting, and more specific inhibitors of this signaling pathway are in development. This review describes the structure of the FGF signaling pathway, delineates its dual roles in angiogenesis and proliferation in NSCLC, evaluates FGF ligand and receptor expression as prognostic biomarkers in NSCLC, and discusses the development of FGF pathway inhibitors for the treatment of lung malignancies.",
keywords = "Angiogenesis, Cellular proliferation, Fibroblast growth factor receptor, Fibroblast growth factors, Nonsmall-cell lung",
author = "Thomas Semrad and Philip Mack",
year = "2012",
month = "3",
doi = "10.1016/j.cllc.2011.08.001",
language = "English (US)",
volume = "13",
pages = "90--95",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Fibroblast growth factor signaling in nonsmall-cell lung cancer

AU - Semrad, Thomas

AU - Mack, Philip

PY - 2012/3

Y1 - 2012/3

N2 - Despite recent progress in the treatment on nonsmall cell lung cancer (NSCLC), outcomes remain suboptimal. Treatment advances that target the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways highlight the need to understand the multiple convergent growth factor signaling pathways involved in the pathogenesis of NSCLC. Signaling through fibroblast growth factors (FGF), long recognized for its pro-angiogenic activity, has recently emerged as a contributing factor in the pathogenesis and progression of NSCLC through an autocrine signaling loop. In addition, this pathway may function as a mechanism of resistance to anti-EGFR and anti-VEGF treatment. Clinical experience with FGF receptor (FGFR) inhibitors is mounting, and more specific inhibitors of this signaling pathway are in development. This review describes the structure of the FGF signaling pathway, delineates its dual roles in angiogenesis and proliferation in NSCLC, evaluates FGF ligand and receptor expression as prognostic biomarkers in NSCLC, and discusses the development of FGF pathway inhibitors for the treatment of lung malignancies.

AB - Despite recent progress in the treatment on nonsmall cell lung cancer (NSCLC), outcomes remain suboptimal. Treatment advances that target the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signaling pathways highlight the need to understand the multiple convergent growth factor signaling pathways involved in the pathogenesis of NSCLC. Signaling through fibroblast growth factors (FGF), long recognized for its pro-angiogenic activity, has recently emerged as a contributing factor in the pathogenesis and progression of NSCLC through an autocrine signaling loop. In addition, this pathway may function as a mechanism of resistance to anti-EGFR and anti-VEGF treatment. Clinical experience with FGF receptor (FGFR) inhibitors is mounting, and more specific inhibitors of this signaling pathway are in development. This review describes the structure of the FGF signaling pathway, delineates its dual roles in angiogenesis and proliferation in NSCLC, evaluates FGF ligand and receptor expression as prognostic biomarkers in NSCLC, and discusses the development of FGF pathway inhibitors for the treatment of lung malignancies.

KW - Angiogenesis

KW - Cellular proliferation

KW - Fibroblast growth factor receptor

KW - Fibroblast growth factors

KW - Nonsmall-cell lung

UR - http://www.scopus.com/inward/record.url?scp=84857407325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857407325&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2011.08.001

DO - 10.1016/j.cllc.2011.08.001

M3 - Article

C2 - 21959109

AN - SCOPUS:84857407325

VL - 13

SP - 90

EP - 95

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -